Johnson & Johnson Family of Companies
United States
2622 articles about Johnson & Johnson Family of Companies
-
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results - March 15, 2023
3/15/2023
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 18th to review first-quarter results.
-
Johnson & Johnson Announces Pricing of $7.75 Billion of Senior Notes Issued by Kenvue Inc.
3/8/2023
Johnson & Johnson announced that Kenvue Inc., a wholly owned subsidiary of Johnson & Johnson, priced an offering of the following series of senior unsecured notes in an aggregate principal amount of $7.75 billion.
-
Zhongchao Inc. Renews Partnership with Johnson & Johnson (China)
2/23/2023
Zhongchao Inc. announced the renewal of the partnership between Zhongchao Medical Technology Co., Ltd., of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements and Johnson & Johnson Investment Limited.
-
Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D. -
Johnson & Johnson to Participate in the Barclays Global HealthCare Conference
2/14/2023
Johnson & Johnson will participate in the Barclays Global HealthCare Conference on Tuesday, March 14th, at the Loews Miami Beach Hotel, Miami Beach, Florida.
-
Johnson & Johnson Names Paula A. Johnson, President of Wellesley College, to its Board of Directors
2/14/2023
Johnson & Johnson announced that Paula A. Johnson, MD, MPH, President of Wellesley College, has been appointed to its Board of Directors.
-
Johnson & Johnson Appoints Dr. John Reed as Executive Vice President, Pharmaceuticals, R&D
2/13/2023
Johnson & Johnson announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D.
-
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer
2/7/2023
Ankyra Therapeutics today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*.
-
Johnson & Johnson to Participate in the Cowen 43rd Annual HealthCare Conference
2/2/2023
Johnson & Johnson will participate in the Cowen 43rd Annual HealthCare Conference on Tuesday, March 7th, at the Boston Marriott Copley Place, Boston, MA.
-
Bronwyn Brophy is appointed new CEO of Vitrolife AB (publ)
2/1/2023
Bronwyn Brophy is Irish and has extensive experience of leading positions in Global Life Science and Medtech companies such as Thermo Fisher Scientific, Medtronic and Johnson & Johnson.
-
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
1/24/2023
Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022.
-
Johnson & Johnson discontinued the Phase III trial of an investigational HIV vaccine regimen Wednesday after an independent review showed it was ineffective at preventing disease. -
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen. -
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2023
1/3/2023
Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2023 of $1.13 per share on the company’s common stock.
-
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter 2022 Results
12/13/2022
Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, January 24th to review fourth-quarter results.
-
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
12/7/2022
Johnson & Johnson (NYSE: JNJ) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9th, at the Westin St. Francis in San Francisco, CA.
-
Johnson & Johnson announced it was acquiring all outstanding shares of Abiomed for $16.6 billion to expand Abiomed's cardiovascular technologies and increase patient access.
-
The FDA has greenlit the use of Johnson & Johnson’s Tecvayli in heavily pretreated adult patients with relapsed or refractory multiple myeloma. -
Johnson & Johnson will lay off 64 employees from its Manhattan-based pharmaceutical supplies business in the early part of 2023. -
Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round.